Gene therapy—is it really a sound investment prospect?
Article in TrialSite News
Daniel O’Connor, founder and CEO TrialSite News
I’ve been having some great conversations with Daniel O’Connor at TrialSite News.
Here are the publication’s Mission & Values:
TrialSite’s mission is to drive awareness, introduce transparency, and facilitate engagement among people all over the world, from pharmaceutical professionals and academic researchers to regulators and healthcare professionals along with a wide array of the consuming public.
We value transparency, objectivity, and the scientific method in pursuit of the truth wherever it may lead us.
Hopefully, I’m not wrong in thinking subscribers to INSIDE PHARMA will appreciate these sentiments.
We have just completed an article together, titled Gene therapy—is it really a sound investment prospect? - albeit it’s published under just my name. Daniel provided the investor speak to my knowledge of the terrain.
The principle is that investment decisions based on the fundamentals of good industrial and business practice can drive pos…